Efficacy of Quadruplet Therapy with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone as Initial Treatment for High-Risk Multiple Myeloma Patients in China: Findings from a Multi-Center Real-World Study - Scorecard - MDSpire
Advertisement
Efficacy of Quadruplet Therapy with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone as Initial Treatment for High-Risk Multiple Myeloma Patients in China: Findings from a Multi-Center Real-World Study
Clinical Scorecard: Efficacy of Quadruplet Therapy with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone as Initial Treatment for High-Risk Multiple Myeloma Patients in China: Findings from a Multi-Center Real-World Study
At a Glance
Category
Detail
Condition
High-Risk Multiple Myeloma (HRMM)
Key Mechanisms
Quadruplet therapy with daratumumab, bortezomib, lenalidomide, and dexamethasone (D-VRd) enhances treatment efficacy in high-risk patients.
Target Population
Patients with newly diagnosed multiple myeloma (NDMM) and high-risk cytogenetic abnormalities.
Care Setting
Multi-center hospitals in China.
Key Highlights
D-VRd shows superior progression-free survival (PFS) compared to VRd in high-risk NDMM patients.
High-risk cytogenetic abnormalities (HRCAs) include t(4;14), t(14;16), del(17p), and gain/amp(1q21).
Patients with ≥2 HRCAs are classified as ultra-high-risk (UHiR) MM.
Daratumumab enhances depth of response and maintains longer-lasting minimal residual disease (MRD)-negative status.
The study emphasizes the need for further validation of quadruplet therapy in routine practice.
Guideline-Based Recommendations
Diagnosis
Diagnosis of NDMM according to IMWG criteria.
Management
Induction therapy with D-VRd followed by ASCT for eligible patients.
Monitoring & Follow-up
Evaluate progression-free survival (PFS) and overall survival (OS) as primary endpoints.
Risks
Monitor for adverse events graded according to NCI CTCAE version 5.0.
